STOCK TITAN

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Stoke Therapeutics, Inc. (Nasdaq: STOK) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. ET. The presentation will discuss the company’s innovative RNA-based medicines aimed at addressing severe diseases through upregulating protein expression. A live audio webcast will be accessible via the Investors & News section on Stoke’s website, with a replay available for 30 days post-event. Stoke is recognized for its proprietary TANGO approach and ongoing clinical trials for STK-001 in Dravet syndrome, as well as STK-002 for optic nerve disorders.

Positive
  • None.
Negative
  • None.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET (11:15 a.m. PT).

A live audio webcast of the presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow Stoke on Twitter at @StokeTx.

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

What is the date and time of Stoke Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Stoke Therapeutics will present on January 10, 2023, at 2:15 p.m. ET.

Where can I watch the Stoke Therapeutics presentation?

The presentation will be available as a live audio webcast on the Investors & News section of Stoke's website.

What is Stoke Therapeutics' focus in biotechnology?

Stoke Therapeutics focuses on addressing severe diseases by upregulating protein expression with RNA-based medicines.

What are STK-001 and STK-002?

STK-001 is in clinical testing for Dravet syndrome, while STK-002 is being developed for autosomal dominant optic atrophy.

How long will the replay of the webcast be available?

The replay of the webcast will be available for 30 days following the presentation.

Stoke Therapeutics, Inc.

NASDAQ:STOK

STOK Rankings

STOK Latest News

STOK Stock Data

613.36M
50.49M
4.67%
110.93%
12.72%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BEDFORD